| Literature DB >> 12069854 |
Isabelle Laffont1, Vladimir V Shuvaev, Olivier Briand, Sophie Lestavel, Anne Barbier, Naoyuki Taniguchi, Jean-Charles Fruchart, Véronique Clavey, Gérard Siest.
Abstract
Glycation is responsible for disruption of lipoprotein functions leading to the development of atherosclerosis in diabetes. The effects of apolipoprotein E (apoE) glycation were investigated with respect to its interaction with receptors. The interaction of apoE with the low density lipoprotein receptor (LDL-R) and scavenger receptor A (SR-A) was measured by competition experiments performed using, respectively, on a human fibroblast cell line 125I-LDL, and on a murine macrophage cell line (J774) 125I-acetylated LDL, and unlabeled apoE/phospholipid complexes. Glycated apoE binding to heparin and heparan sulfates (HS) was assessed by surface plasmon resonance (SPR) technology. Site-directed mutagenesis was then performed on Lys-75, the major glycation site of the protein. The prepared mutant protein proved to be useful as a tool to study the role of Lys-75 in apoE glycation. The findings showed that, although glycation has no effect on apoE binding either to the LDL-R or to SR-A, it impairs its binding to immobilized heparin and HS. The glycation of Lys-75 was found to be proceed rapidly and contributed significantly to total protein glycation. We propose that, in the case of diabetes, glycation may lead to the atherogenicity of apoE-containing lipoproteins disturbing their uptake via the HS proteoglycan pathway.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12069854 DOI: 10.1016/s1388-1981(02)00188-9
Source DB: PubMed Journal: Biochim Biophys Acta ISSN: 0006-3002